Abstract
It was found that second-line or thereafter therapies for patients with non-small cell lung cancer (NSCLC) who failed previous chemotherapy yielded a modest survival benefit. However, whether elderly patients (> or =70 years) benefit and are as suitable for salvage therapy as nonelderly patients (<70 years) are unknown. Whether epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is more favorable than chemotherapeutic agents as a salvage therapy agent in elderly patients with NSCLC is also undetermined. We retrospectively reviewed and updated the data of our patients with NSCLC who received second-line salvage therapies, classified them into elderly and nonelderly groups, and compared the efficacy, toxicities, and survival of the patients. Four hundred sixty-one cases were reviewed. The nonelderly group had a similar response rate, control rate, and median survival time than the elderly group (p = 0.2, p = 0.9, and p = 0.5, respectively). The median progression-free time was numerically longer in the elderly than the nonelderly patients (p = 0.08). The nonelderly group had statistically insignificantly less hematologic toxicities than the elderly group, but more nausea and vomiting. In addition, the use of EGF...Continue Reading
References
Jan 16, 1999·Journal of the National Cancer Institute
Feb 12, 2000·Chest·C W KuoR P Perng
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Oct 24, 2002·American Journal of Clinical Oncology·Yuh-Min ChenJacqueline Whang-Peng
Feb 13, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yuh-Min ChenReury-Perng Perng
Dec 10, 2003·American Journal of Clinical Oncology·Yuh-Min ChenJacqueline Whang-Peng
Apr 27, 2005·Journal of the Chinese Medical Association : JCMA·Yuh-Min ChenReury-Perng Perng
Jul 9, 2005·Chest·Yuh-Min ChenJacqueline Whang-Peng
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jan 26, 2006·Journal of Chemotherapy·Yuh-Min ChenChun-Ming Tsai
Mar 24, 2006·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yuh-Min ChenJacqueline Whang-Peng
Apr 13, 2006·Chest·Yuh-Min ChenJacqueline Whang-Peng
Mar 14, 2007·Cancer·Yuh-Min ChenJacqueline Whang-Peng
Sep 4, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Kun-Ta ChouJacqueline Whang-Peng
Sep 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Riichiroh MaruyamaMasahiro Fukuoka
Sep 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lucio CrinòMichael Cullen
Nov 26, 2008·Lancet·Edward S KimJean-Yves Douillard
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Citations
May 4, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E FelipUNKNOWN Panel Members
Apr 23, 2011·Medicine·Jenn-Yu WuPan-Chyr Yang
Mar 19, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A G PallisM O'Brien
Oct 17, 2015·Expert Review of Anticancer Therapy·Paola Claudia SaccoCesare Gridelli
Oct 13, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Anne S TsaoWaun Ki Hong
Aug 13, 2014·Tuberculosis and Respiratory Diseases·Seok Jeong LeeJung Hyun Chang
Jun 18, 2014·American Journal of Clinical Oncology·Wen-Shuo WuYuh-Min Chen
Jun 17, 2014·Oncology Letters·Chu-Yun HuangJacqueline Whang-Peng
Aug 24, 2016·Asia-Pacific Journal of Clinical Oncology·Yung-Hung LuoYuh-Min Chen
Jul 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A G PallisM O'Brien